| Vol. 13.32 – 26 August, 2021 |
| |
|
|
| Seven CADA compounds were examined for reduction of cellular sortilin expression and progranulin-induced breast cancer stem cell propagation. [Journal of the American Chemical Society] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that triple inhibition with fulvestrant, CDK4/6i and AKT inhibitor durably impaired growth of breast cancer cells, prevented progression and reduced metastasis of tumor xenografts resistant to CDK4/6i-fulvestrant combination or fulvestrant alone. [Nature Communications] |
|
|
|
| In vitro chemical induction with RepSox generated chemically induced mammary epithelial cells (MECs) with milk secreting functions from goat ear fibroblasts (GEFs). Single-cell RNA sequencing revealed that during the reprogramming process, GEFs may have sequentially undergone embryonic ectoderm-like and different MEC developmental states. [Biomaterials] |
|
|
|
| Researchers found that except for SP1, the other tethering partners of ERβ were down-regulated in TNBC, meaning that the tumor-suppressive functions of ERβ were severely compromised. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Employing the mouse mammary tumor virus–PyMT mouse model of metastatic breast cancer, scientists compared the complete elimination of β-catenin with the specific ablation of its signaling outputs in mammary tumor cells. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors identified a circRNA termed circ-EIF6, which predicted a poorer prognosis and correlated with clinicopathological characteristics in a cohort of TNBC patients. Functionally, they showed that circ-EIF6 promoted the proliferation and metastasis of TNBC cells in vitro and in vivo. [Molecular Therapy] |
|
|
|
| Investigators showed that the expression of integrin α3 (ITGα3) and integrin β5 (ITGβ5) was upregulated in highly metastatic MDA-MB-231, MDA-MB-231BO breast cancer cell lines but was downregulated in poorly metastatic MCF-7 breast cancer cell line, which may have been the key targets of osthole’s anti-metastatic action. [Acta Pharmacologica Sinica] |
|
|
|
| Homemade ethanol-based garlic extract was administered to breast tumor cell lines grown under moderate hypoxia. Cell cycle, epithelial-to-mesenchymal transition and cancer stem cell markers were evaluated. [Biomedicine & Pharmacotherapy] |
|
|
|
| Researchers presented comprehensive proteomes comprised of >9,000 total proteins, and >15,000 phosphopeptides, from normal primary human mammary epithelia at lineage resolution from ten women ranging in age from 19 to 68. Results were biologically validated with cell-based assays. [iScience] |
|
|
|
| Investigators evaluated the anti breast-cancer activity, biocompatibility, and toxicity of poly(d,l)-lactic-co-glycolic acid-encapsulated quercetin nanoparticles. Activity against CAL51 and MCF7 cell lines was assessed by DNA fragmentation assays, fluorescence microscopy, and acridine-orange, and propidium-iodide double-stainings. [Nanomedicine] |
|
|
|
| The authors investigated the function and underlying mechanisms of novel circPDCD11 in TNBC aerobic glycolysis and revealed that circPDCD11 expression was significantly upregulated in TNBC tissues and cells. [Cell Death Discovery] |
|
|
|
| Scientists evaluated the phenotype switching associated with drug resistance in breast cancer cell lines and highlighted the role of the cancer stem cell marker CD24 in the dynamics of cell plasticity and the acquirement of drug resistance. [Scientific Reports] |
|
|
|
| Hormone receptor positive, reduction mammoplasty-derived human breast epithelial progenitors were exposed to a short-term, pregnancy-level of estradiol, and their subsequent response to estradiol stimulation was analyzed. [Scientific Reports] |
|
|
|
|
| Investigators elucidate the general characteristics, potential mechanisms and targeted therapy of long non-coding RNAs (LncRNAs) and discuss the emerging functions of LncRNAs in breast cancer. [Molecular Therapy-Nucleic Acids] |
|
|
|
|
| BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announced a multi-year, non-exclusive license agreement with ImaginAb Inc., a biotechnology company focused on developing next-generation immuno oncology imaging agents and radiopharmaceutical therapies. [BriaCell Therapeutics Corp.] |
|
|
|
|
| November 15 – 19, 2021 Virtual |
|
|
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| Purdue University – West Lafayette, Indiana, United States |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
|